Notably, as an alternative to mosaic pathogenic genetic variants, we have also recently found constitutional mosaic promoter methylation of BRCA1 to be associated with a significantly increased risk of triple‐negative breast cancer and high‐grade serous ovarian cancer [48, 49]. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.